A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Lilly

Status and phase: Not yet enrolling; Phase 1

Conditions: Overweight; Obesity

Treatments: Drug: LY4167586; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07225556

J6L-MC-YIAA (Other Identifier)

27659 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Enrollment: 84 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participant must be 21 for Singapore site
• Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
• Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent [%] body weight change)

Exclusion criteria

• Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
• Is an individual of childbearing potential (IOCBP)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

84 participants in 3 patient groups, including a placebo group

LY4167586 (Cohorts A1 to A6)

Experimental group

Description:

LY4167586 administered subcutaneously (SC)

Treatment:

Drug: LY4167586

Drug: LY4167586

LY4167586 (Cohorts A1 to A6) Placebo

Placebo Comparator group

Description:

LY4167586 administered SC

Treatment:

Drug: Placebo

LY4167586 (Cohort B)

Experimental group

Description:

LY4167586 administered intravenously (IV)

Treatment:

Drug: LY4167586

Drug: LY4167586